GLP-1s: a long-term solution?
Obesity is now widely understood to be a long-term, chronic disease [1,2]. Body weight is regulated by biological mechanisms that act to defend a relatively stable level over time, such that weight loss achieved in the short term commonly returns towards this defended range[3,4].
GLP-1 receptor agonists appear to act in line with this biology. While treatment is ongoing, they are highly effective at enabling weight loss [4,5,10]. However, this effect does not persist once treatment is stopped [13]. Appetite returns and substantial weight regain is common[5,13].
In this respect, GLP-1 drugs resemble treatments used for other chronic diseases such as hypertension or type 2 diabetes: they are effective while taken, but their benefits diminish when treatment is withdrawn. These drugs are generally prescribed for ongoing use rather than as fixed short courses [1].
This framing creates a central tension. If GLP-1 drugs function like long-term disease-modifying therapies, are they suited to long-term use in practice? At present, their use in this way is problematic—not because the model is wrong, but because of constraints related to cost, safety uncertainty, and healthcare systems.*
Cost
The first major problem is cost. These drugs remain expensive while under patent protection, with limited scope for near-term price reductions [12].
Within NHS England, commissioning and funding arrangements for GLP-1 therapy can include specialist initiation requirements and time-limited funding or continuation criteria [1,12]. These restrictions appear to be driven by commissioning and cost considerations, rather than clear evidence that shorter treatment durations are clinically optimal. Even for private patients, long-term use is financially prohibitive for most.
Long-term use without long-term safety certainty
A second problem is that long-term use is being contemplated in the absence of truly long-term safety certainty. While the GLP-1 drug class has been in use for over two decades, the newer and more potent agents have only been available for a much shorter period. Medium-term safety data, including cardiovascular outcome trials in high-risk populations, are thus far reassuring with respect to major adverse cardiovascular events [9]. However, like most large clinical trials, these studies were not designed to detect rare adverse effects,
very long-latency outcomes, or cumulative risks over decades of use, particularly in populations treated primarily for obesity rather than diabetes [10,11].
There are also serious adverse events to be aware of, including gallbladder and biliary disease, and a longstanding clinical concern about pancreatitis [2,8,11].‡
When weighed against the dramatic benefits seen in clinical trials, these risks often appear acceptable. However, because substantial weight regain is common after discontinuation, the risk–benefit calculation becomes more complicated if treatment cannot be continued long term [5].
Practical approaches in the real world
In practice, there are three broad approaches.
First, for patients who can afford private treatment, long-term use may be considered, with a clear-eyed discussion about costs, uncertainties, and the limitations of current knowledge regarding long-term safety.†
Second, we can accept fluctuations in weight, with patients starting GLP-1 therapy, stopping after weight loss has been achieved, and potentially returning for further courses if weight is regained. While not ideal, this may represent a pragmatic compromise between cost and effectiveness. After discontinuation, substantial weight regain is common, but on average patients do not regain all of the weight lost, and a modest net weight loss relative to baseline often persists [5,13].
Third, GLP-1 drugs can be used as a means of initial weight loss, followed by attempts at weight maintenance using other strategies. After stopping GLP-1 therapy, conventional lifestyle counselling alone often does not prevent substantial weight regain [5,6,7]. Combinations of approaches—such as tapering GLP-1 doses to lower long-term maintenance levels, structured exercise programmes, or switching to alternative weight-loss medications—may help preserve some of the gains achieved [6]. Of course, other medications may bring their own long-term risks.
Where this leaves us
None of these options is perfect. In reality, this leaves us waiting for three key developments.
First, we need to closely monitor emerging long-term safety data as wider and longer use accumulates. New risks—or changes in how existing risks are weighed against benefits—may yet alter the calculus.
Second, we await cheaper alternatives, either through the arrival of off-patent formulations or through price reductions driven by increased competition.
Third, and perhaps most importantly, we need better evidence on the most effective combinations of lifestyle, behavioural, and pharmacological interventions for maintaining weight loss in patients who have completed or come off GLP-1 treatment.
Footnotes
* Responses to GLP-1 therapy vary considerably between individuals. The discussion here reflects average outcomes observed in clinical trials and population-level data; for some patients, long-term use may involve fewer practical or clinical tensions.
‡ Post-marketing reports and biological plausibility have driven concern about pancreatitis with GLP-1 receptor agonists. However, large randomised trials and meta-analyses have not demonstrated a clear increase in pancreatitis risk. As a precautionary measure, clinical guidance recommends discontinuing GLP-1 therapy if pancreatitis is suspected or confirmed [8,11].
† GLP-1 receptor agonists are associated with improvements in several cardiometabolic risk markers while treatment is ongoing. There is currently limited evidence that these benefits persist in full once treatment is discontinued, and it is biologically plausible that benefits diminish as weight is regained.
Commentary
This essay reflects the evidence, regulatory landscape, and market dynamics as they stood at the time of writing.
This article sets out our clinical thinking on GLP-1–based weight loss, drawing on the current evidence base. It is written for clinicians, researchers, and readers with a strong interest in medical weight management, and is shared here for transparency alongside our clinical service.
Frequently Asked Questions
These answers provide a general overview. For detailed explanations, evidence summaries, and treatment comparisons, see our in-depth guides in the Knowledge Hub.
Are GLP-1s suitable chronic treatments?
GLP-1s: a long-term solution?
Obesity is now widely understood to be a long-term, chronic disease [1,2]. Body weight is regulated by biological mechanisms that act to defend a relatively stable level over time, such that weight loss achieved in the short term commonly returns towards this defended range[3,4].
GLP-1 receptor agonists appear to act in line with this biology. While treatment is ongoing, they are highly effective at enabling weight loss [4,5,10]. However, this effect does not persist once treatment is stopped [13]. Appetite returns and substantial weight regain is common[5,13].
In this respect, GLP-1 drugs resemble treatments used for other chronic diseases such as hypertension or type 2 diabetes: they are effective while taken, but their benefits diminish when treatment is withdrawn. These drugs are generally prescribed for ongoing use rather than as fixed short courses [1].
This framing creates a central tension. If GLP-1 drugs function like long-term disease-modifying therapies, are they suited to long-term use in practice? At present, their use in this way is problematic—not because the model is wrong, but because of constraints related to cost, safety uncertainty, and healthcare systems.*
Cost
The first major problem is cost. These drugs remain expensive while under patent protection, with limited scope for near-term price reductions [12].
Within NHS England, commissioning and funding arrangements for GLP-1 therapy can include specialist initiation requirements and time-limited funding or continuation criteria [1,12]. These restrictions appear to be driven by commissioning and cost considerations, rather than clear evidence that shorter treatment durations are clinically optimal. Even for private patients, long-term use is financially prohibitive for most.
Long-term use without long-term safety certainty
A second problem is that long-term use is being contemplated in the absence of truly long-term safety certainty. While the GLP-1 drug class has been in use for over two decades, the newer and more potent agents have only been available for a much shorter period. Medium-term safety data, including cardiovascular outcome trials in high-risk populations, are thus far reassuring with respect to major adverse cardiovascular events [9]. However, like most large clinical trials, these studies were not designed to detect rare adverse effects,
very long-latency outcomes, or cumulative risks over decades of use, particularly in populations treated primarily for obesity rather than diabetes [10,11].
There are also serious adverse events to be aware of, including gallbladder and biliary disease, and a longstanding clinical concern about pancreatitis [2,8,11].‡
When weighed against the dramatic benefits seen in clinical trials, these risks often appear acceptable. However, because substantial weight regain is common after discontinuation, the risk–benefit calculation becomes more complicated if treatment cannot be continued long term [5].
Practical approaches in the real world
In practice, there are three broad approaches.
First, for patients who can afford private treatment, long-term use may be considered, with a clear-eyed discussion about costs, uncertainties, and the limitations of current knowledge regarding long-term safety.†
Second, we can accept fluctuations in weight, with patients starting GLP-1 therapy, stopping after weight loss has been achieved, and potentially returning for further courses if weight is regained. While not ideal, this may represent a pragmatic compromise between cost and effectiveness. After discontinuation, substantial weight regain is common, but on average patients do not regain all of the weight lost, and a modest net weight loss relative to baseline often persists [5,13].
Third, GLP-1 drugs can be used as a means of initial weight loss, followed by attempts at weight maintenance using other strategies. After stopping GLP-1 therapy, conventional lifestyle counselling alone often does not prevent substantial weight regain [5,6,7]. Combinations of approaches—such as tapering GLP-1 doses to lower long-term maintenance levels, structured exercise programmes, or switching to alternative weight-loss medications—may help preserve some of the gains achieved [6]. Of course, other medications may bring their own long-term risks.
Where this leaves us
None of these options is perfect. In reality, this leaves us waiting for three key developments.
First, we need to closely monitor emerging long-term safety data as wider and longer use accumulates. New risks—or changes in how existing risks are weighed against benefits—may yet alter the calculus.
Second, we await cheaper alternatives, either through the arrival of off-patent formulations or through price reductions driven by increased competition.
Third, and perhaps most importantly, we need better evidence on the most effective combinations of lifestyle, behavioural, and pharmacological interventions for maintaining weight loss in patients who have completed or come off GLP-1 treatment.
Footnotes
* Responses to GLP-1 therapy vary considerably between individuals. The discussion here reflects average outcomes observed in clinical trials and population-level data; for some patients, long-term use may involve fewer practical or clinical tensions.
‡ Post-marketing reports and biological plausibility have driven concern about pancreatitis with GLP-1 receptor agonists. However, large randomised trials and meta-analyses have not demonstrated a clear increase in pancreatitis risk. As a precautionary measure, clinical guidance recommends discontinuing GLP-1 therapy if pancreatitis is suspected or confirmed [8,11].
† GLP-1 receptor agonists are associated with improvements in several cardiometabolic risk markers while treatment is ongoing. There is currently limited evidence that these benefits persist in full once treatment is discontinued, and it is biologically plausible that benefits diminish as weight is regained.
Commentary
This essay reflects the evidence, regulatory landscape, and market dynamics as they stood at the time of writing.
Frequently Asked Questions
GLP-1–based medications are highly effective at producing weight loss while treatment is ongoing, but obesity itself behaves like a long-term condition rather than a short-term problem that can be permanently “fixed”.
Whether GLP-1s function as a long-term solution therefore depends on more than biology alone. In theory, continued treatment can help maintain lower weight and improved health markers. In practice, long-term use is often limited by affordability, access rules within healthcare systems, and uncertainty about safety over decades of continuous use, which is difficult to establish for any relatively new long-term therapy.
For many people, the question is not whether long-term therapy makes biological sense, but whether it is practically sustainable.
Weight regain after stopping GLP-1 therapy is common and reflects normal biology rather than a lack of willpower.
Body weight is regulated by systems that tend to defend a familiar range. When weight is reduced — whether through dieting, medication, or surgery — these systems respond by increasing hunger signals and encouraging the body to return toward its previous level.
While on GLP-1 therapy, appetite is dampened and fullness signals are strengthened, making lower intake easier. When treatment is stopped, these effects fade and appetite often returns toward its earlier level, even though eating habits may not have changed consciously.
At the same time, after weight loss the body typically needs fewer calories than before. Energy use remains lower, so the amount of food required to maintain weight is smaller than it once was. This means that eating in a way that previously maintained weight can now slowly lead to regain.
Together, a stronger biological drive to eat and lower ongoing energy needs make weight maintenance more difficult once treatment is withdrawn.
While GLP-1 therapy is ongoing, many people see improvements in blood sugar control, blood pressure, lipid levels, and other cardiometabolic risk markers.
What happens after stopping treatment varies between individuals. Some people maintain much of their weight loss and retain associated health benefits, particularly if weight regain is limited. Others experience partial or substantial weight regain over time.
Current evidence suggests that many metabolic improvements are closely linked to body weight itself. If a significant amount of weight is regained, associated improvements in blood sugar, blood pressure, and lipid profiles often diminish as well. There is limited evidence that these benefits persist fully if substantial weight regain occurs.
This is why follow-up and longer-term planning matter, rather than assuming benefits will automatically persist after treatment ends.
There is no single “correct” duration of treatment.
It is often more helpful to think in terms of ongoing planning rather than a predetermined end point. This usually involves an initial phase focused on achieving weight loss, followed by a maintenance phase that considers how weight and health will be supported over time.
For some people, this may involve continued GLP-1 therapy with regular review. For others, it may involve transitioning to alternative strategies after stopping treatment. What matters most is that follow-up and longer-term planning are built in from the outset.
The main barriers are cost, access, and uncertainty about very long-term use.
These medications remain expensive, and healthcare systems often restrict prescribing through specialist initiation, continuation criteria, or time-limited funding. These constraints are largely driven by affordability and commissioning decisions rather than evidence that short treatment courses are biologically optimal.
As a result, many people who might benefit from long-term therapy are unable to access it consistently, even when treatment is clinically effective.
Most people experience gastrointestinal side effects, particularly early in treatment. These commonly include nausea, vomiting, diarrhoea, or constipation and often improve with time or dose adjustment.
Less common but clinically important risks include gallbladder and biliary disease. There has also been longstanding concern about pancreatitis; while large trials have not demonstrated a clear increase in risk, ongoing monitoring remains important.
What remains uncertain are long-latency risks (effects that may only appear after many years), very rare adverse events that are difficult to detect in trials, and cumulative effects of long-term use over decades — especially in people treated primarily for obesity rather than diabetes. These uncertainties are typical of most chronic therapies early in their widespread use.
There is no single “correct” duration that applies to everyone.
The case for longer-term treatment is strongest for those who stand to benefit the most. This includes those whose overall health risk is higher — for example in people with type 2 diabetes, hypertension, sleep apnoea, established cardiovascular risk, or a history of repeated weight regain after previous weight loss attempts.
The decision is not based on an assumption that treatment should be short-term for most people. Rather, it reflects an individual assessment of potential benefit, practical feasibility, safety considerations, and how weight and health are likely to be managed over time.
Evidence is still evolving.
In practice, some clinicians use dose tapering or lower maintenance doses to reduce appetite rebound and support transition to other strategies. However, tapering is not guaranteed to prevent weight regain, and robust comparative data are limited.
Close monitoring during dose reduction is important, regardless of approach.
Maintaining weight loss after stopping GLP-1 therapy is usually harder than achieving the initial loss.
Lifestyle advice alone often struggles to prevent regain. Structured exercise programmes, attention to protein and fibre intake, behavioural support, and — in some cases — alternative medications may improve the chances of maintaining at least part of the weight loss.
Successful maintenance typically involves multiple supports rather than a single intervention.
Yes — this pattern occurs commonly in real-world care.
Because long-term continuous treatment is often limited by cost or access, some people use GLP-1 therapy for a period, stop after weight loss, and later restart if weight is regained. This represents a pragmatic compromise rather than an ideal strategy.
Over time, this approach may still result in a modest net weight reduction compared with baseline, but each course should involve reassessment of safety, benefit, and long-term planning.
The risk–benefit balance depends strongly on whether ongoing treatment is realistically achievable.
If continuous therapy is feasible, benefits and risks can be assessed similarly to other long-term treatments for chronic disease. If treatment is likely to be interrupted due to cost or access, the calculation changes, because benefits may diminish after stopping while some risks accumulate during use.
Shared decision-making should therefore consider health risk, likelihood of continuation, alternative options after discontinuation, and how outcomes will be monitored over time.
Several important questions remain unanswered.
Key gaps include clearer long-term safety data over decades, better evidence on how to maintain weight loss after stopping treatment, and more real-world data outside clinical trials. In particular, we need studies that test combined approaches — for example, how medication, structured exercise, nutritional strategies, and behavioural support can be sequenced or combined to support durable outcomes.
Filling these gaps will be essential for guiding sustainable and equitable long-term use.
1. Lingvay I, Cohen RV, le Roux CW, Sumithran P. Obesity in adults. Lancet. 2024.
2. Garvey WT et al. AACE consensus statement: evaluation and treatment of adults with obesity. Endocr Pract. 2025.
3. Heymsfield SB, Wadden TA. Mechanisms, pathophysiology, and management of obesity. N Engl J Med. 2017.
4. Laughlin MR et al. Physiology of the weight-reduced state. Obesity. 2021.
5. Berg S et al. Discontinuing GLP-1 receptor agonists and body habitus. Obesity Reviews. 2025.
6. Jensen SBK et al. Healthy weight loss maintenance with exercise and GLP-1 therapy. EClinicalMedicine. 2024.
7. Mozaffarian D et al. Nutritional priorities to support GLP-1 therapy for obesity. Am J Clin Nutr. 2025.
8. Monami M et al. Safety issues with GLP-1 receptor agonists. Diabetes Obes Metab. 2017.
9. Lincoff AM et al. Semaglutide and cardiovascular outcomes in obesity without diabetes. N Engl J Med. 2023.
10. Singh S, Loke YK. Drug safety assessment in clinical trials. Trials. 2012.
11. Moiz A et al. The expanding role of GLP-1 receptor agonists. EClinicalMedicine. 2025.
12. Ansari S et al. Time to unshackle the medical treatment of obesity in the NHS. Clin Med (Lond). 2024.
13. Wilding JPH et al. Weight regain after withdrawal of semaglutide: STEP-1 extension. Diabetes Obes Metab. 2022.
About the Author
Dr Blunt is a UK-licensed General Practitioner with an Extended Role in Lifestyle Medicine, and a specialist interest in metabolic health, obesity management, and evidence-based medicine. He has completed accredited training in medical weight management, including the national SCOPE obesity programme.
His writing focuses on translating high-quality research into clear, practical explanations to help readers understand complex topics in obesity, medication safety, and long-term health.
GMC: 7527933
Medical Disclaimer
This information is for educational purposes only and should not be considered medical advice. Always consult with a qualified healthcare professional for diagnosis and treatment of any medical condition. All content on this website is for general information only and does not replace personalised medical advice. See full Medical Disclaimer.